Yes, orphan drugs in Malaysia are eligible for special registration pathways. The National Pharmaceutical Regulatory Agency (NPRA) offers expedited review processes to facilitate faster access to these drugs, addressing rare diseases with unmet medical needs. This approach aims to encourage the development and availability of treatments for rare conditions.
